Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 6.3% Following Analyst Upgrade

Spyre Therapeutics, Inc. (NASDAQ:SYRE) shares shot up 6.3% on Friday after Wells Fargo & Company raised their price target on the stock from $40.00 to $50.00. Wells Fargo & Company currently has an overweight rating on the stock. Spyre Therapeutics traded as high as $39.69 and last traded at $40.2020. 39,453 shares were traded during trading, a decline of 94% from the average session volume of 624,201 shares. The stock had previously closed at $37.81.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Spyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. JonesTrading upgraded Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a report on Monday, December 1st. Citigroup initiated coverage on Spyre Therapeutics in a research note on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $70.00 target price on shares of Spyre Therapeutics in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Spyre Therapeutics has a consensus rating of “Buy” and a consensus price target of $53.44.

Insiders Place Their Bets

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the transaction, the chief executive officer directly owned 657,540 shares of the company’s stock, valued at approximately $21,567,312. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 45,000 shares of company stock worth $1,387,500 over the last three months. 15.43% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

Institutional Investors Weigh In On Spyre Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC raised its position in shares of Spyre Therapeutics by 26.0% in the second quarter. Affinity Asset Advisors LLC now owns 606,678 shares of the company’s stock valued at $9,082,000 after purchasing an additional 125,000 shares during the period. Franklin Resources Inc. grew its stake in Spyre Therapeutics by 4.6% in the 2nd quarter. Franklin Resources Inc. now owns 795,275 shares of the company’s stock valued at $11,905,000 after buying an additional 34,647 shares in the last quarter. AlphaQuest LLC grew its stake in Spyre Therapeutics by 1,485.1% in the 3rd quarter. AlphaQuest LLC now owns 66,163 shares of the company’s stock valued at $1,109,000 after buying an additional 61,989 shares in the last quarter. Intech Investment Management LLC raised its holdings in Spyre Therapeutics by 22.1% during the 2nd quarter. Intech Investment Management LLC now owns 24,945 shares of the company’s stock valued at $373,000 after acquiring an additional 4,517 shares during the period. Finally, Candriam S.C.A. lifted its position in shares of Spyre Therapeutics by 64.4% during the third quarter. Candriam S.C.A. now owns 404,362 shares of the company’s stock worth $6,777,000 after acquiring an additional 158,332 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

The stock has a market capitalization of $3.35 billion, a P/E ratio of -20.77 and a beta of 3.15. The stock has a fifty day moving average price of $33.40 and a 200 day moving average price of $25.35.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). Research analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.